[1] FELDMAN E, KALAYCIO M, WEINER G. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. 2003(2). doi:10.1038/sj.leu.2402803
[2] DUZKALE H, PAGLIARO L C, ROSENBLUM M G. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. 2003(6). doi:10.1016/S1083-8791(3)00129-0
[3] SIEVERS E L, LARSON R A, STADTMAUER E A. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. 2001(13)
[4] LARSON R A, BOOGAETS M, ESTEY E. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using mylotarg (gemtuzumab ozogamicin). 2002(9). doi:10.1038/sj.leu.2402677
[5] PICCALUGA P P, MARTINELLI G, RONDONI M. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. 2004(9). doi:10.1080/1042819042000219485
[6] LO-COCO F, CIMINO G, BRECCIA M. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. 2004(7). doi:10.1182/blood-2004-04-1550
[7] BALAIAN L, BALL E D. Direct effect of bispecific anti-CD33x anti-CD64 antibody on proliferation and signaling in myeloid cells. 2001(12)
[8] BALAIAN L, BALL E D. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x antiCD64 antibodies, 2004(8)
[9] MATTHEWS D C, APPELBAUM F R, EARY J F. Phase I study of (131) I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. 1999(4)
[10] BUCHMANN I, KULL T, GLATTING G. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5with regard to suitability for myeloablative radioimmunotherapy. 2003
[11] VALLERA D A, ELSON M, BRECHBIEL M W. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice, 2003(2)
[12] SCHEIBENBOGEN C, LETSCH A, THIEL E. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. 2002(6). doi:10.1182/blood-2002-01-0163
[13] GAO L, BELLANTUONO I, ELSASSER A. Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1, 2000(7)
[14] ROSENFELD C, CHEEVER M A, GAIGER A. WT1 in acute leukemia,chronic myelogenous leukemia and myelodysplastic syndrome:therapeutic potential of WT1 targeted therapies. 2003(7). doi:10.1038/sj.leu.2402988
[15] 吴晓雄, 汪月增, 裴雪涛. WT1反义寡核苷酸对白血病细胞增殖和凋亡的影响. 中华血液学杂志1999(12)
[16] RENSHAW J, ORR R M, WALTON M I. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment:antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival, 2004(11)
[17] DAVIES J A, LADOMERY M, HOHENSTEIN P. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1tumour suppressor is required for nephron differentiation. 2004(2). doi:10.1093/hmg/ddh015
[18] LEVIS M, TSE K F, SMITH B D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. 2001(3). doi:10.1182/blood.V98.3.885
[19] SMITH B D, LEVIS M, BERAM M. Single agent CEP-701,a novel FLT3 inhibitor,shows biologic and clinical in patients with refractory acute myeloid leukemia. 2004(10). doi:10.1182/blood-2003-11-3775
[20] OFARRELL A M, YUEN H A, SMOLICH B. Effects of SU5416,a small molecule tyrosine kinase receptor inhibitor,on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. 2004(7)
[21] FIEDLER W, SERVE H, DOHNER H. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. 2005(3). doi:10.1182/blood-2004-05-1846
[22] STONE R M, DEANGELO D J, KLIMEK V. Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor,PKC412. 2005(1). doi:10.1182/blood-2004-03-0891
[23] GRISWOLD I J, SHEN L J, LA ROSEE P. Effects of MLN518,a dual FLT3 and KIT inhibitor,on normal and malignant hematopoiesis. 2004(9). doi:10.1182/blood-2003-05-1669
[24] REED J C. Apoptosis-targeted therapies for cancer. 2003(1). doi:10.1016/S1535-6108(2)00241-6
[25] CIOCA D P, AOKIOK Y, KIYOSAWA K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. 2003(2). doi:10.1038/sj.cgt.7700544
[26] LUO K Q, ChANG D C. The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. 2004(1). doi:10.1016/j.bbrc.2004.04.027
[27] CARTER B Z, MILELLA M, ALTIERI D C. Cytokineregulated expression of survivin in myeloid leukemia. 2001(9). doi:10.1182/blood.V97.9.2784
[28] CARTER B Z, WANG R Y, SCHOBER W D. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells, 2003(5)
[29] COMA S, NOE V, LAVARINO C. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. 2004(2). doi:10.1089/1545457041526290
[30] 李莉萍, 梁念慈, 罗超权. 存活素SiRNA表达质粒的构建及其对MCF-7细胞细胞周期和增殖的调控. 癌症2004(7). doi:10.3321/j.issn:1000-467X.2004.07.002 |
